Text Size

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT00898872
First received: May 9, 2009
Last updated: May 17, 2013
Last verified: May 2013
History of Changes
  Purpose

RATIONALE: Collecting and storing samples of tissue from patients with non-Hodgkin lymphoma to study in the laboratory may help the study of cancer in the future.

PURPOSE: This laboratory study is collecting and storing tissue samples from patients with relapsed or recurrent non-Hodgkin lymphoma after treatment on a Southwest Oncology Group (SWOG) clinical trial.


Condition Intervention
Lymphoma
 Other: cryopreservation

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lymphoma
U.S. FDA Resources

Further study details as provided by Southwest Oncology Group:

Primary Outcome Measures:
  • Acquisition of snap-frozen lymphoma tissues [ Time Frame: July 2011 ] [ Designated as safety issue: No ]

Enrollment: 32
Study Start Date: March 1993
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Acquire fresh snap-frozen lymphoma tissue from patients with relapsed or recurrent non-Hodgkin lymphoma after treatment on a Southwest Oncology Group (SWOG) clinical trial.
  • Establish a standard set of procedures for routine acquisition, banking, and study of lymphoma tissues within the SWOG.
  • Use repository tissue to establish clinical correlations via presently activated phenotyping studies and future projected molecular studies assessing specimen DNA and RNA status.
  • Examine the biology of therapy failure in relationship to changes in pretreatment and post-treatment immunophenotypic data.

OUTLINE: This is a multicenter study.

Tissues collected at biopsy are snap-frozen and archived for future molecular and genetic studies.

PROJECTED ACCRUAL: Not specified

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who consented to SWOG 9245 for banking

Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of relapsed or recurrent non-Hodgkin lymphoma (NHL)

  • Previously registered on 1 of the following SWOG clinical trials for previously untreated NHL:

    • SWOG-8410
    • SWOG-8503
    • SWOG-8508
    • SWOG-8516
    • SWOG-8736
    • SWOG-8809
    • SWOG-8907
    • SWOG-8954
    • SWOG-9125
    • SWOG-9240
    • SWOG-9320
    • SWOG-9349
    • SWOG-9432
    • SWOG-9501
    • SWOG-9703
    • SWOG-S9704
    • SWOG-9800
  • Tissue samples of relapsed or recurrent disease available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898872

  Show 82 Study Locations
Sponsors and Collaborators
Southwest Oncology Group
National Cancer Institute (NCI)
Investigators
Study Chair: Thomas Grogan, MD University of Arizona
Study Chair: Thomas P. Miller, MD University of Arizona
Study Chair: Richard I. Fisher, MD James P. Wilmot Cancer Center
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Southwest Oncology Group
ClinicalTrials.gov Identifier: NCT00898872     History of Changes
Other Study ID Numbers: CDR0000455162, SWOG-9245, U10CA032102
Study First Received: May 9, 2009
Last Updated: May 17, 2013
Health Authority: United States: Federal Government

Keywords provided by Southwest Oncology Group:
recurrent grade 3 follicular lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent adult Burkitt lymphoma
recurrent adult grade III lymphomatoid granulomatosis
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent mantle cell lymphoma
recurrent marginal zone lymphoma
recurrent small lymphocytic lymphoma
 extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
splenic marginal zone lymphoma
Waldenström macroglobulinemia
adult nasal type extranodal NK/T-cell lymphoma
recurrent childhood grade III lymphomatoid granulomatosis
recurrent childhood large cell lymphoma
recurrent childhood lymphoblastic lymphoma
recurrent childhood small noncleaved cell lymphoma
childhood diffuse large cell lymphoma
childhood immunoblastic large cell lymphoma
childhood Burkitt lymphoma
childhood nasal type extranodal NK/T-cell lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, Large-Cell, Immunoblastic
Neoplasms by Histologic Type
Neoplasms
 Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on May 21, 2013